Gilead Sciences' Lenacapavir Demonstrated 100% Efficacy in Preventing HIV
Gilead Sciences, Inc. (GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women.

PURPOSE 1 met its key efficacy endpoints . . .